Usefulness of Bifidobacterium longum BB536 in Elderly Individuals With Chronic Constipation: A Randomized Controlled Trial
Takeda T, Asaoka D, Nojiri S, Yanagisawa N, Nishizaki Y
Published in American Journal of Gastroenterology
Methodology
Randomised, double-blind, placebo-controlled parallel-group superiority trial in 80 Japanese adults (mean age 77.9) with chronic constipation given B. longum BB536 5 x 10^10 CFU or placebo daily for 4 weeks.
Key Findings
The primary endpoint (change in Constipation Scoring System total score) was not significant (P=0.074), although the BB536 group improved from baseline (P<0.01) and stool frequency improved versus placebo (P=0.008).
Conclusions
BB536 produced within-group and stool-frequency improvements but failed its primary endpoint in elderly chronic constipation.
Limitations
Small sample; short 4-week duration; primary endpoint negative, so secondary findings are exploratory.
Supplements Studied
The primary end point was not significant (P = 0.074), although there was significant improvement (P < 0.01) in the BB536 group from baseline to week 4.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Industry (Morinaga Milk) supported
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.